Alliance and Collaboration - Additional Information (Details) - USD ($)					3 Months Ended		6 Months Ended		12 Months Ended	57 Months Ended
	Dec. 31, 2018	Nov. 09, 2018	Aug. 16, 2018	May 07, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2020	Mar. 22, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expensed to costs of goods sold					$ 319,666,000	$ 296,381,000	$ 633,244,000	$ 606,124,000
Research and development					45,572,000	48,016,000	81,951,000	101,874,000
JSP License And Commercialization Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term			10 years
Accrued up-front license contingent payment											$ 50,000,000
JSP And Lannett Company Transition Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of non-refundable payment	$ 4,000,000	$ 47,000,000
Expensed to costs of goods sold						37,000,000	0
JSP And Lannett Company Transition Agreement | Unsold Inventory
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expensed to costs of goods sold									$ 1,000,000
Biosimilar Licensing and Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement maximum contingent payments amount				$ 72,000,000
Research and development					5,000,000	0	5,000,000	1,000,000
Astra Zeneca
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expensed to costs of goods sold					$ 5,000,000	$ 5,000,000	$ 9,000,000	$ 9,000,000
Astra Zeneca | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement reduced royalty										$ 30,000,000